|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 美国国立老化研究所与阿尔茨海默病协会诊断指南写作组:阿尔茨海默病源性轻度认知障碍诊断标准推荐显示文摘美国国立老化研究所(NIA)和阿尔茨海默病协会(ADA)组织了一个工作组,负责阿尔茨海默病(AD)痴呆前症状阶段——即本文所称的AD源性轻度认知障碍(MCI)的诊断标准的制订及完善。该工作组制订了以下两套标准:(1)在缺乏相应条件进行先进影像技术及脑脊液检查时,医务人员适用的核心临床标准;(2)适用于包括临床试验在内的科学研究的研究标准。后者纳入了基于影像技术及脑脊液检查的生物标志物的应用。并根据所出现的生物标志物的性质,将最终MCI诊断的确定性程度分为4个级别。而要使生物标志物有效应用于诊断,并在社区医疗服务中规范使用,尚需做大量的工作。 | McKhann GM Knopman DS Chertkow H Hyman BT Jack CR Jr Kawas CH Klunk WE Koroshetz WJ Manly JJ Mayeux R Mohs RC Morris JC Rossor MN Schehens P Carrillo MC Thies B Weintraub S Phelps CH 贾建平(译) 陆璐(译) 张逸驰(译) 黄丽黄(译) 礼媛(译) | 2012 | 中华神经科杂志2012，45，5： | 51 |
| 2 | 美国国立老化研究所与阿尔茨海默病协会诊断指南写作组:阿尔茨海默病痴呆诊断标准的推荐显示文摘由美国国立老化研究所(NIA)和阿尔茨海默病(AD)协会组织了一个工作组,负责修订1984年版AD痴呆的诊断标准。旨在确保修订后的标准具有足够的灵活性,既可供缺乏神经心理学测验、先进的影像技术和脑脊液检查措施的普通医务人员使用,也可供具备上述措施的科研、临床试验的专业研究者使用。新的标准广泛适用于各种原因的痴呆以及专门针对AD痴呆的标准,保留了1984年版标准中的“很可能的AD痴呆”的总体框架。在过去27年的经验基础上,工作组对临床诊断标准做了一些修改,保留了“可能的AD痴呆”的术语,但对其进行了更有针对性的重新定义。在科研用的“很可能的和可能的AD痴呆”的诊断标准中纳入了生物标志物证据。AD痴呆的核心临床标准仍将是临床实践中诊断的基础,但用生物标志物证据来提高AD痴呆诊断的病理生理学特异性也被人们寄予厚望。要实现AD痴呆的生物标志物诊断,还有许多工作摆在面前。 | McKhann GM Knopman DS Chertkow H Hyman BT Jack CR Jr Kawas CH Klunk WE Koroshetz WJ Manly J J Mayeux R Mohs RC Morris JC Rossor MN Scheltens P Carrillo MC Thies B Weintraub S Phelps CH 贾建平(译) 陆璐(译) 张逸驰(译) 黄丽(译) 韩阅(译) | 2012 | 中华神经科杂志2012，45，5： | 52 |
| 3 | 美国国立老化研究所与阿尔茨海默病协会诊断指南写作组:阿尔茨海默病临床前阶段的定义显示文摘阿尔茨海默病(AD)的病理生理过程在痴呆诊断的多年前就开始了。这一长期的AD“临床前”阶段是治疗干预的关键机会,但需进一步阐明AD的病理级联过程和临床症状出现之间的联系。美国国立老化研究所和AD协会召集了一个国际工作组对AD生物标志物、流行病学和神经心理学的证据进行综述并提出建议,以确定能够预测由“正常”认知到轻度认知功能障碍(MCI)及AD痴呆的最佳预测指标。根据目前已有的主要科学证据,我们提出了一个概念性的框架和用于操作的研究标准,以通过纵向临床研究来验证和改进这些模型。这些建议仅用于研究目的,目前不涉及临床应用。我们希望这些建议能提供一个共识,以推进临床前AD的研究,最终推动更早期治疗干预的进展,使得一些疾病减缓药物的疗效发挥最大。 | Sperling RA Aisen PS Beckett LA Bennett DA Craft S Fagan AM Iwatsubo T Jack CR Jr Kaye J Montine TJ Park DC Reiman EM Rowe CC Siemers E Stern Y Yaffe K Carrillo MC Thies B Morrison-Bogorad M Wagster MV Phelps CH 贾建平(译) 郭起浩(译) 黄丽(译) 陆璐(译) 张逸驰(译) 邢怡(译) | 2012 | 中华神经科杂志2012，45，5： | 22 |
| 4 | 年龄>80岁患者的收缩压轨迹、衰弱和全因死亡率:电子健康记录队列研究显示文摘血压随年龄而升高,老年人高血压患病率较高。收缩压升高可能是老年人心血管病的最重要危险因素。最近几项大型临床试验显示,降压药降低血压的同时可降低老年人的心血管事件和死亡率。对年龄〉80岁患者进行降压治疗的老老年高血压试验(hypertension in the very elderly trial, | Ravindrarajah R Hazra NC Hamada S Charlton J Jackson SHD Dregan A Gulliford MC 练桂丽 叶鹏 | 2017 | 中华高血压杂志2017，25，7： | 22 |
| 5 | Soy-based renoprotection显示文摘Chronic kidney disease(CKD) is a significant publich ealth problem as risk factors such as advanced age, obesity, hypertension and diabetes rise in the global po-pulation. Currently there are no effective pharmacologic treatments for this disease. The role of diet is important for slowing the progression of CKD and managing symptoms in later stages of renal insufficiency. While low protein diets are generally recommended, maintaining adequate levels of intake is critical for health. There is an increasing appreciation that the source of protein may also be important. Soybean protein has been the most extensively studied plant-based protein in subjects with kidney disease and has demonstrated renal protective properties in a number of clinical studies. Soy protein consumption has been shown to slow the decline in estimated glomerular filtration rate and significantly improve proteinuria in diabetic and non-diabetic patients with nephropathy. Soy's beneficial effects on renal function may also result from its impact on certain phy-siological risk factors for CKD such as dyslipidemia, hypertension and hyperglycemia. Soy intake is also associated with improvements in antioxidant status and systemic inflammation in early and late stage CKD pati-ents. Studies conducted in animal models have helped to identify the underlying molecular mechanisms that may play a role in the positive effects of soy protein on renal parameters in polycystic kidney disease, metabolically-induced kidney dysfunction and age-associated prog-ressive nephropathy. Despite the established relationship between soy and renoprotection, further studies are needed for a clear understanding of the role of the cellular and molecular target(s) of soy protein in main-taining renal function. | Nancy J Mc Graw Elaine S Krul Elizabeth Grunz-Borgmann Alan R Parrish | 2016 | World Journal of Nephrology2016，5，3： | 5 |
| 6 | Resection of a rapid-growing 40-cm giant liver hemangioma显示文摘Hemangiomas are the most frequent benign tumors of the liver. Most hemangiomas are asymptomatic and therefore largely diagnosed only in routine screening tests. Usually they are small and require no specific treatment. In some situations they can reach great dimensions, causing some discomfort to the patient. Resection of liver hemangioma is indicated in cases of great dimension tumors causing symptoms such as pain, nausea or bloating caused by compression of adjacent organs. We report a case of a rare giant hemangioma with rapid growth in short time:a 50 year old female reported to our institution with a 40 cm giant liver hemangioma and then underwent a left hepatectomy. | Andreas JM Koszka Fabio G Ferreira Caio GG de Aquino Maurício A Ribeiro André S Gallo Elisa MC Aranzana Luiz A Szutan | 2010 | World Journal of Hepatology2010，2，7： | 3 |
| 7 | 颈动脉硬化进展与病程≥10年的高血压治疗之间的关系:多种族动脉粥样硬化研究显示文摘尚未有前瞻性多种族队列对抗高血压药物类别和动脉硬化进展的相关性进行研究。该研究所有受试者基线均患高血压,定义为血压≥140/90 mm Hg(1mm Hg=0.133kPa)或服用降压药物治疗。在5个时间点评估药物的服用情况和血压水平。通过超声在基线时和平均随访(9.4±0.5)年后测定右颈总动脉的杨氏弹性模量和扩张系数。 | Gepner AD Tedla Y Colangelo LA Tattersall MC Korcarz CE Kaufman JD Liu K Burke GL Shea S Greenland P Stein JH 刘莉 叶鹏 | 2016 | 中华高血压杂志2016，24，11： | 2 |
| 8 | Blood classical monocytes phenotype is not altered in primary non-small cell lung cancer显示文摘AIM: To evaluate the M1 and M2 monocyte phenotype in patients with non-small cell lung cancer(NSCLC) compared to controls. Also, to examine the expression of Th1 and Th2 cytokines in plasma of NSCLC vs controls. METHODS: Freshly prepared peripheral blood mononuclear cells samples were obtained from patients with NSCLC(lung adenocarcinoma and squamous cell lung carcinoma) and from non-cancer controls. Flow cytometry was performed to investigate M1 and M2 phenotypes in peripheral monocytes(classical monocytes CD14+, CD45+ and CD16-) using conventional surface markers. Th1 and Th2 cytokine production was alsoanalysed in the plasma using cytometric bead array technique. RESULTS: There were no significant difference in expression of M1(HLA-DR) and/or M2 markers(CD163 and CD36) markers on classical monocytes in patients with NSCLC compared to non-cancer controls. Expression of CD11 b, CD11 c, CD71 and CD44 was also shown to be similar in patients with NSCLC compared to noncancer controls. Th1 and Th2 cytokines [interleukin(IL)-1β, IL-2, IL-4, IL-5, IL-8, IL-10, IL-12(p70), tumor necrosis factor(TNF)-α, TNF-β, and interferon-γ] analysis revealed no significant difference between patients with NSCLC and non-cancer controls. CONCLUSION: This study shows no alteration in peripheral monocyte phenotype in circulating classical monocytes in patients with NSCLC compared to noncancer controls. No difference in Th1 and Th2 cytokine levels were noted in the plasma of these patients. | Saleh A Almatroodi Christine F Mc Donald Allison L Collins I an A Darby Dodie S Pouniotis | 2014 | World Journal of Clinical Oncology2014，5，5： | 2 |
| 9 | 神经生长因子增强小胶质细胞的神经保护作用显示文摘小胶质细胞是脑组织内的防御细胞,但在病理和生理条件下,调控小胶质细胞活化的因子并不十分清楚。本研究发现,神经生长因子(NGF)可以增强小胶质细胞的神经保护和抗炎功能。在体内和体外研究中都发现,小胶质细胞表达NGF受体。原代培养小胶质细胞,给予NGF处理,转录本分析结果显示,NGF对小胶质细胞的运动、吞噬和降解吞噬物的能力均产生影响。对功能的研究显示,NGF可增加小胶质细胞的膜运动能力和胞饮作用;在体研究显示,NGF可激活小胶质细胞释放向外整流电流,调节周围谷氨酸能神经元的神经传递。既往研究提示,小胶质细胞有清除脑内Aβ肽的功能,本研究观察了NGF对小胶质细胞吞噬能力的影响。结果显示,NGF可促进小胶质细胞通过Trk A途径清除Aβ,并加速其降解。此外,NGF还可减轻由Aβ导致的炎症激活。特异性激活小胶质细胞还可以减轻由Aβ导致的神经元树突损伤和长时程增强抑制。在对离体脑片的研究中,我们也发现NGF可以促进小胶质细胞吞噬Aβ。综上所述,本研究证实NGF可以促进小胶质细胞活化,活化的小胶质细胞通过抗炎作用减轻Aβ聚集,发挥神经保护作用。 | 唐颖馨 Rizzi C Tiberi A Giustizieri M Marrone MC Gobbo F Carucci NM Meli G Arisi I D'Onofrio M Marinelli S Capsoni S Cattaneo A | 2018 | 神经损伤与功能重建2018，13，2： | 2 |
| 10 | Isolation of Salmonid microsatellite loci and their application to the population genetics of Canadian east coast stocks of Altantic salmon显示文摘 | Mc Connel S | 1995 | Aquaculture1995，，137： | 2 |
| 11 | Complete genomes of two clinical Staphylococcus aureus strains:evidence for the rapid evolution of virulence and drug resistance显示文摘 | Holden MT Feil EJ Lindsay JA Peacock SJ Day NP Enright MC Foster TJ Moore CE Hurst L Atkin R Barron A Bason N Bentley SD Chillingworth C Chillingworth T Churcher C Clark L Corton C Cronin A Doggett J Dowd L Feltwell T Hance Z Harris B Hauser H Holroyd S Jagels K James KD Lennard N Line A Mayes R Moule S Mungall K Ormond D Quail MA Rabbinowitsch E Rutherford K Sanders M Sharp S Simmonds M Stevens K Whitehead S Barrell BG Spratt BG Parkhill J | 2004 | Proc Natl Acad Sci USA2004，101，26： | 1 |
| 12 | Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption显示文摘 | SAADOUN S PAPADOPOULOS MC HARA-CHIKUMA M | 2005 | Nature2005，434，7034： | 1 |
| 13 | Intra-industry trade and specification in processed agricultural products显示文摘 | Mc Corriston S Sheldon I M | 1991 | Review of Agricultural Economics1991，，13： | 1 |
| 14 | Vascular smooth muscle cell apoptosis induces interleukin-l-directed inflammation:effects of hyperlipidemia-mediated inhibition of phagocytosis 显示文摘 | Clarke MC Talib S Figg NL | 2010 | Circ Res2010，106，2： | 1 |
| 15 | Effect of wood species on property and weathering performance of wood plastic composites显示文摘 | James S Fabiyi Armando G Mc Donald | 2010 | Composites Part A2010，41，： | 1 |
| 16 | Brown adipocytes are novel sites of expression and regulation of adiponectin and resistin显示文摘 | Viengchareun S Zennaro MC Pascual-Le | 2002 | FEBS Lett2002，532，3： | 1 |
| 17 | Impairment of angiogenesis and cell migration by targetedaquaporin-1 gene disruption显示文摘 | Saadoun S Papadopoulos MC Hara-Chikuma M | 2005 | Nature2005，434，7034： | 1 |
| 18 | Anti-canc-er effects of artesunate in a panel of chemoresistant neuro-blastoma cell lines显示文摘 | Michaelis M Kleinschmidt MC Barth S | 2010 | Biochem Pharmacol2010，79，： | 1 |
| 19 | Genetic immunization of outbred mice with thyrotropin receptor cDNA provides a model of Graves' disease显示文摘 | Costagliola S Many MC Denef JF | 2000 | J Clin Invest2000，105，6： | 1 |
| 20 | Results of a comprehensive infection control program for reducing surgical- site infections in coronary artery bypass surgery 显示文摘 | Mc Conkey S Ecuyer PBL | 1999 | Infect Control Hospital Epidemiol1999，8，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员